**APTCT, 30 April 2015** 



## How to Assess Biological Activity of Inflammarory Plaque?: Combined OFDI-NIRF Molecular Imaging


# Kim Jin Won, M.D., Ph.D., F.A.C.C.



## Korea University Guro Hospital Multimodal Imaging and Theranostic Lab




### **MOLI with Near-infrared Fluorochrome (NIRF)**



#### Lee SK, Kim JW. CCIR 2015

### **Fully Integrated OCT-NIRF Catheter**



### Fibrin-Targeting Stent Thrombosis

Kim JW et al. Nature Medicine 2011


## **High-Speed 2nd Generation OCT-NIRF**

### **Real-time data acquisition of OCT-NIRF**


- Rotation speed: upto 100 rps
- Blood elimination: just flushing
- Pullback speed: upto 40mm/s
- No crosstalk
- Real-time OCT-NIRF Synchronization




**Circulation Cardiovasc Interv 2014** 




## **OCT-NIRF in a Beating Coronary Plaque**




### In Vivo OCT-NIRF




### **Ex Vivo** Validation




### **NIRF - Plaque Type**



### **Excellent Reproducibility**



ICC = 0.823 (82.3% consistency) p < 0.001




**ICC = Interclass Correlation Coefficient** 


### **Corroborrative Immunostaining**

PM-2K (MAC) ORO (Lipid) In Vivo OCT-NIRF CLSM SMA A Advanced, Inflamed, Lipid-rich в Thick, non-inflamed 500 ur 900 ur С Focal, .48 Inflamed 600 un 500.um D Normal 200 u

## **DES-associated Inflammation**



## **Coronary OCT-NIRF Imaging In Vivo**




#### **Vulnerable Plaque**

#### **DES related inflammation**

# **Clinical Trial Roadmap Launching**


Fixed




Preclinical









### **Targeting Strategy with a Novel Optical Probe**





JB Kim,---, Kim JW. AHA 2014. (submitted)

### **High-risk Plaque Mac Subset Imaging**











Mannose receptor binding ligand NIRF dye (Cy5.5 or 7) PEG Glycol chitosan nanoparticle



submitted

### In Vivo Plaque MMR MOLI IPH May Modify Macrophage Subset Behavior?



### **OCT-Label Free FLIM Imaging**





Table 1 Comparison between Intravascular Imaging Techniques

	X-ray angio.	IVUS	OCT	<b>IVUS-NIRS</b>	OCT-NIRF	OCT-FLIM
Resolution	+	++	+++	++	+++	+++
Speed	+++	+	+++	+	+++	+++
Lumen area	1 <u>-</u> 1	+++	+++	+++	+++	+++
TCFA	-	+	+++	++	+++	+++
Lipid plaques	1.40	+	+	+++	++	+++
Plaque burden	-	+++	+	+++	+	+
Thrombus	-	+	++	+	++	+++
Stent analysis	-	+	+++	+	+++	+++
Inflammation	2.55	50 70	+		+++	+++
Safety	+++	+++	+++	+++	+	+++

#### Samsung Research Funding Center for Future Technology

### **Personalized Theranostic Strategy**



#### **NRF Creative Research Initiative Program**

# Conclusion

- A fully integrated OCT-NIRF imaging with a clinically approved NIRF enhancing ICG was able to accurately identify high-risk coronary plaque and assess DES-associated coronary inflammation.
- This highly translatable dual-modal, structural-molecular imaging strategy could enhance our capabilities to understand high-risk plaque biology and is expected to spur personalized approaches to estimate plaque vulnerability in near future.
- A newly developed, plaque macrophage targeting NIRF probe could be utilizable for high-risk plaque imaging, and needs to be further validated regarding acute toxicity and long-term safety.

### Acknowledgements

#### Korea University, CV MT Lab

Jin Won Kim Jae Joong Lee Sunki Lee Ja Hyun Choi Joon Woo Song Woong Seo

KAIST, BPI I

Wang-Yuhl, Oh Sun-Joo Jang

#### KAIST, NOM Lab

DaeGab Gweon

Byeong Won Cheon Sun Won Kim Ji Bak Kim Eunjin Park Hee Dong Kim Sang Pyo Hong

Han Sam Cho

**Jiheun Ryu** 

Tae Shik Kim

### Hanyang University, BME

Hongki Yoo Jun Young Kim Hyeong Soo Nam Min Woo Lee Chang-Soo Kim

#### Korea Basic Science Institute Kyeongsoon Park Seung-Hae Kwon Ok Kyu Park

National Research Foundation Funded by Korea Government to JW Kim, HK Yoo and KS Park (2012R1A2A2A046108) Basic Science Research Program through NRF by MEST to HK Yoo (2012R1A1A1041203), Korean Vascular Research Working Group R&D grant to JW Kim (2012R1200691), KUMC Speciel R&D grant to JW Kim (2012K1220481)